Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

BACKGROUND: Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is to clarify the reality of HPD in patients with advanced hep...

Descripción completa

Detalles Bibliográficos
Autores principales: Yumita, Sae, Ogasawara, Sadahisa, Nakagawa, Miyuki, Maruta, Susumu, Okubo, Tomomi, Itokawa, Norio, Iino, Yotaro, Obu, Masamichi, Haga, Yuki, Seki, Atsuyoshi, Kogure, Tadayoshi, Ishino, Takamasa, Ogawa, Keita, Fujiwara, Kisako, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Saito, Tomoko, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Itobayashi, Ei, Atsukawa, Masanori, Koma, Yoshihiro, Azemoto, Ryosaku, Ito, Kenji, Mizumoto, Hideaki, Kato, Jun, Kato, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067175/
https://www.ncbi.nlm.nih.gov/pubmed/37003980
http://dx.doi.org/10.1186/s12876-023-02731-5

Ejemplares similares

Ejemplares similares